Literature DB >> 7594236

Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans.

D Tepavcević1, Z Giljević, I Aganović, M Korsić, S Halimi, E Suchanek, T Jelić, B Kozić, V Plavsić.   

Abstract

The role of serotonin in the insulin hypoglycemia (IH) stimulated secretion of prolactin (PRL), growth hormone (GH), adrenocorticotropin (ACTH) and cortisol (F) was studied in a group of 12 normal subjects during the control period after placebo and a consecutive six-day treatment with 20 mg ritanserin (RIT) per day. RIT failed to affect the baseline levels of all the four hormones as well as the PRL response to IH (p > 0.5). The serum GH response to IH was moderately diminished after RIT, the reduction of integrated trapezoidal area under hormone curves (nAUC) being 50.7% +/- 6.9% (p < 0.005). Furthermore, RIT was found to slightly decrease the plasma ACTH response to IH, the reduction of nAUC being 36.3% +/- 2.6% (p < 0.005). Decrease in the corresponding plasma F response to IH was accompanied by 29.1% +/- 2.4% reduction of nAUC (p < 0.005). According to our results, serotonin-S2 receptors appeared to be moderately involved in IH-induced release of GH, but slightly in that of ACTH, leaving unaffected that of PRL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594236     DOI: 10.1007/BF03349740

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Inhibition of stress-induced hyperprolactinaemia.

Authors:  B Corenblum; M Whitaker
Journal:  Br Med J       Date:  1977-11-19

2.  Pulsatile growth hormone secretion: suppression by hypothalamic ventromedial lesions and by long-acting somatostatin.

Authors:  J B Martin; L P Renaud; P Brazeau
Journal:  Science       Date:  1974-11-08       Impact factor: 47.728

3.  Inhibition of hypoglycemia-induced cortisol secretion by the serotonin antagonist cyproheptadine.

Authors:  J W Plonk; C H Bivens; J M Feldman
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

4.  Human prolactin and growth hormone release during surgery and other conditions of stress.

Authors:  G L Noel; H K Suh; J G Stone; A G Frantz
Journal:  J Clin Endocrinol Metab       Date:  1972-12       Impact factor: 5.958

5.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

6.  Effect of adrenergic receptor blockade on cortisol and GH response to insulin-induced hypoglycemia in man.

Authors:  D Jezová-Repceková; I Klimes; J Jurcovicová; M Vigas
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-02

7.  Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system.

Authors:  G P Bernini; G F Argenio; M S Vivaldi; C Del Corso; M Sgrò; F Franchi; M Luisi
Journal:  Horm Res       Date:  1989

8.  Effect of the antihistaminic agents meclastine and dexchlorpheniramine on the response of human growth hormone to arginine infusion and insulin hypoglycemia.

Authors:  A E Pontiroli; G Viberti; A Vicari; G Pozza
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

9.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

10.  Effect of an antiserotoninergic drug, metergoline, on the ACTH and cortisol response to insulin hypoglycemia and lysine-vasopressin in man.

Authors:  F Cavagnini; U Raggi; P Micossi; A Di Landro; C Invitti
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

View more
  1 in total

1.  Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease.

Authors:  N Sonino; G A Fava; F Fallo; A Franceschetto; P Belluardo; M Boscaro
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.